Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252

Allowed: IDH1 mutation

IDH wt or IDH mutated

Allowed: IDH2 mutation

IDH wt or IDH mutated

Must have received: radiation therapy — standard

The subject must have received standard radiation therapy plus temozolomide and be refractory to radiation therapy plus temozolomide prior to enrollment.

Must have received: alkylating agent (temozolomide) — standard

The subject must have received standard radiation therapy plus temozolomide and be refractory to radiation therapy plus temozolomide prior to enrollment.

Cannot have received: immunotherapeutic agents

Exception: unless the patient has recovered from the expected toxic effects of such therapy

Treated with immunotherapeutic agents prior to MVR-C5252 treatment, within 4 weeks

Cannot have received: alkylating agent

Exception: unless the patient has recovered from the expected toxic effects of such therapy

alkylating agents within 4 weeks

Cannot have received: nitrosourea

Exception: unless the patient has recovered from the expected toxic effects of such therapy

nitrosoureas within 6 weeks

Cannot have received: cytotoxic chemotherapy

Exception: unless the patient has recovered from the expected toxic effects of such therapy

non-alkylating chemotherapy within 2 weeks before enrollment

Cannot have received: antiangiogenic agent (bevacizumab)

Treated with antiangiogenic agents (i.e., bevacizumab) within 4 weeks before biopsy

Cannot have received: oncolytic virus

Prior treatment with any oncolytic virus, cell therapy or gene therapy.

Cannot have received: cell therapy

Prior treatment with any oncolytic virus, cell therapy or gene therapy.

Cannot have received: gene therapy

Prior treatment with any oncolytic virus, cell therapy or gene therapy.

Cannot have received: intracranial implant (Carmustine)

Prior antitumor treatment with intracranial implants, such as Carmustine